Category: CAR T-Cell therapy

Home / CAR T-Cell therapy

Categories

Patient experience of CAR T-cell therapy suffering from acute lymphoblastic leukemia

May 2022: Matthew is a 27-year-old patient with Acute Lymphoblastic Leukemia who was diagnosed in 2015. Unfortunately, the standard treatment of chemotherapy and bone marrow transplantation failed. He...

CAR T-Cell therapy for mantle cell lymphoma (MCL)

Induction therapy followed by stem cell transplantation has maintained a role in the treatment of mantle cell lymphoma (MCL), according to James Gerson, MD, who added that he continues to recommend tr...

JW Therapeutics’ IND is cleared by China NMPA for CAR T-Cell therapy in large B-Cell lymphoma

China's National Medical Products Administration (NMPA) has approved JW Therapeutics' investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in peo...

Can CAR T-Cell manufacturing time be reduced to just one day?

April 2022: Normally, the cell manufacturing procedure for CAR T-cell therapy takes nine to fourteen days; however, researchers at the University of Pennsylvania were able to create functional CAR T c...

CAR T-Cell therapy in solid tumors – A research study

March 2022: Blood vessels are supposed to behave like trees, pouring oxygen into tissues in order for them to flourish and immune cells to clean infections out. The forest, on the other hand, can go a...

CAR T- cell therapy for breast cancer is on the cards

March 2022: According to researchers at the UNC Lineberger Comprehensive Cancer Center, adding a tiny chemical to a treatment process called chimeric antigen receptor-T (CAR-T) cell therapy can boost...

CARVYKTI (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma

March 2022: According to Johnson & Johnson, a therapy developed by the company and its China-based partner Legend Biotech Corp to treat a kind of white blood cell cancer has been approved by the...

CAR-T Cell therapy could be made safer and more widely available with a few adjustments

March 2022: A revolutionary approach to CAR-T Cell therapy has the potential to overturn what has become a medical axiom: that the treatment's remarkable effect on tumours comes at the expense of subs...

CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment cost, latest CAR-T clinical trial recruitment

March 2022: CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment price, cost, the latest CAR-T clinical trial recruitment information summary. The concept of boron neu...

Ciltacabtagene autoleucel is approved for relapsed or refractory multiple myeloma

March 2022: After four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, the Food and Drug Administration ...

Scan the code